Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4078-4085

  Faje, Alexander T ^a   Sullivan, Ryan ^b   Lawrence, Donald ^b   Tritos, Nicholas A ^a   Fadden, Riley ^b   Klibanski, Anne ^a   Nachtigall, Lisa ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; HYPOPHYSIS HORMONE; IPILIMUMAB; PREDNISONE; THYROID HORMONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FOOD AND DRUG ADMINISTRATION; GENDER; GENERAL HOSPITAL; HORMONE DETERMINATION; HUMAN; HYPOPHYSIS DISEASE; HYPOPHYSIS FUNCTION; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; INCIDENCE; LONGITUDINAL STUDY; MALE; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; SURVIVAL TIME; TERTIARY CARE CENTER; THYROTOXICOSIS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; CHEMICALLY INDUCED; HYPOPHYSIS; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPOPITUITARISM; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; PITUITARY GLAND; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84910011365     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2306     Document Type: Review

References (22)

1. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24: 1813-1821.
2. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30: 2046-2054.
3. A phase II efficacy and safety study of ipilimumab monotherapy following completion of chemotherapy in recurrent platinum sensitive ovarian cancer subjects with residual measurable disease (NCT01611558). clinicaltrials.gov. Accessed February 1, 2014.
4. An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy (NCT01585987). clinicaltrials.gov. Accessed February 1, 2014.
5. Phase II trial of gemcitabine, cisplatin, plus ipilimumab as first-line treatment for patients with metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148 (NCT01524991). clinicaltrials.gov. Accessed February 1, 2014.
6. Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Res. 2012;65: 9-22.
7. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98: 1361-1375.
8. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine- related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21: 371-381.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
10. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double- blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11: 155-164.
11. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21: 1712-1717.
12. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13: 6681-6688.
13. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006;29: 455-463.
14. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17: 896-906.
15. Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169: R153-R164.
16. Yervoy. Bristol-Myers Squibb, package insert, revised December 2013. Princeton, NJ: Bristol-Myers Squibb.
17. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of ctla-4 mediates hypophysitis secondary to administration of ctla-4 blocking antibody. Sci Transl Med. 2014;6: 230-245.
18. Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother. 2005;28: 517-524.
19. Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol. 2012;167: 1-5.
20. Andrews S, Holden R. Characteristics and management of immune related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 2012;4: 299-307.
21. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30: 2691-2697.
22. Falorni A, Minarelli V, Bartoloni E, Alunno A, Gerli R. Diagnosis and classification of autoimmune hypophysitis. Autoimmun Rev. 2014;13: 412-416.